Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs-Reference-Cited by-同舟云学术

Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs

Published:2021-10 Issue: Volume: Page:
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Yeung Alan^ORCID,Palmateer Norah E.,Dillon John F.^ORCID,McDonald Scott A.^ORCID,Smith Shanley^ORCID,Barclay Stephen,Hayes Peter C.,Gunson Rory N.,Templeton Kate,Goldberg David J.,Hickman Matthew^ORCID,Hutchinson Sharon J.

Funder

Public Health Scotland

NIHR

Publisher

Elsevier BV

Subject

Hepatology

Reference37 articles.

1. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis,2016

2. How feasible is the global elimination of HCV infection?;Wiktor;Lancet,2019

3. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model;Heffernan;Lancet,2019

4. Blood borne viruses and sexually transmitted infections: Scotland 2017,2017

5. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs;Grebely;Addiction,2019

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reinfection After Hepatitis C Virus Treatment—Keep Testing, Keep Treating;JAMA Network Open;2024-08-26

2. Diagnostic Overshadowing of Chronic Hepatitis C in People With Mental Health Conditions Who Inject Drugs: A Scoping Review;International Journal of Mental Health Nursing;2024-08-05

3. Changes in hepatitis C virus prevalence and incidence among people who inject drugs in the direct acting antiviral era;International Journal of Drug Policy;2024-06

4. Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C Trial;Viruses;2024-05-27

5. Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals;Expert Opinion on Pharmacotherapy;2024-05-02